Global Targeted Radionuclide Drug Supply, Demand and Key Producers, 2023-2029

Global Targeted Radionuclide Drug Supply, Demand and Key Producers, 2023-2029

The global Targeted Radionuclide Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Targeted Radionuclide Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Targeted Radionuclide Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted Radionuclide Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Targeted Radionuclide Drug total market, 2018-2029, (USD Million)

Global Targeted Radionuclide Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Targeted Radionuclide Drug total market, key domestic companies and share, (USD Million)

Global Targeted Radionuclide Drug revenue by player and market share 2018-2023, (USD Million)

Global Targeted Radionuclide Drug total market by Type, CAGR, 2018-2029, (USD Million)

Global Targeted Radionuclide Drug total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Targeted Radionuclide Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Fusion Pharmaceuticals and RadioMedix, Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Targeted Radionuclide Drug market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Targeted Radionuclide Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Targeted Radionuclide Drug Market, Segmentation by Type
Medicine
Inhibitor

Global Targeted Radionuclide Drug Market, Segmentation by Application
Tumors
Thyroid
Others

Companies Profiled:
POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Fusion Pharmaceuticals
RadioMedix, Inc.
Convergent Therapeutics
IONETIX
Clarity Pharmaceuticals
RayzeBio, Inc
AmbioPharm
Bracco Imaging
Navidea
China Isotope & Radiation Corporation
Yantai Dongcheng
Grand Pharma
Hengrui Medicine
Yunnan Baiyao Group
SmartNuclide Biopharma
Sinotau
Hexin Pharmaceutical

Key Questions Answered

1. How big is the global Targeted Radionuclide Drug market?

2. What is the demand of the global Targeted Radionuclide Drug market?

3. What is the year over year growth of the global Targeted Radionuclide Drug market?

4. What is the total value of the global Targeted Radionuclide Drug market?

5. Who are the major players in the global Targeted Radionuclide Drug market?

6. What are the growth factors driving the market demand?